SOURCE: Curidium Medica PLC

May 14, 2008 06:48 ET

Preliminary Results

LONDON--(Marketwire - May 14, 2008) -


                         Curidium Medica plc
                   ("Curidium" or "the Company")


        PRELIMINARY RESULTS FOR THE YEAR ENDED 31 DECEMBER 2007


LONDON, UK, 12 May 2008, Curidium Medica plc, (LSE: CUR), the
personalised medicine company focused on bringing the right drug to the
right patient, announced today its Preliminary Results for the year ended
31 December 2007.



Financial highlights



                                         Year ended           Year ended
                                        31 December          31 December
                                               2007                 2006
Research and Development expenditure     GBP389,994           GBP304,712
Group Operating Loss                   GBP1,292,973           GBP976,558
Group Loss Before Tax                  GBP1,167,659           GBP945,036
Loss per Share                                0.20p                0.24p
Cash out flow from operating
activities                             GBP1,276,104           GBP627,291




Operational highlights

*         Signed partnership agreement with Takeda Research Investment
          Inc. applying Homomatrix® to Major Depressive Disorder
*         Raised GBP2.5 million in subscription agreement
*         Trademarked "PsychINDx" as blood test for Schizophrenia (SZ)
          / Bipolar (BP) Disorder patient subgroups
*         Discovered statistically significantly different patient
          subgroups in SZ/BP Disorder
*         Discovered unique Gene Expression Profiles in blood of SZ/BP
          patient subgroups



Gosse Bruinsma, Executive Chairman of Curidium said:"This has been a
transformational year for Curidium in which its
proprietary technology Homomatrix® consecutively proved to identify the
statistically significant patient sub-groups, thereby proving the
technology strategy, the Balance Sheet was strengthened with a significant
fund raising  in July 2007 and we signed a strategic research alliance with
Takeda Research which included a GBP1.25m investment."In 2008 overall
market conditions are encouraging with both regulatory
and 'pharmaco-economics' driving interest in effective personalised
medicine solutions. We have stepped up our marketing of PsychINDxTM to a
number of preferred partners and have received a favourable reception to
date. We continue to believe and drive towards our overriding company
objective: to bring theright drug to the right patient."


Click on the following link or paste into your browser to view the full
announcement:

http://www.rns-pdf.londonstockexchange.com/rns/4090U_1-2008-5-14.pdf
- Ends -



For further information please contact:

Gosse B. Bruinsma, M.D. +31 (0) 629 046 397
Executive Chairman, Curidium Medica plc

Rob Smith +44 (0) 20 7383 5345
Finance Director, Curidium Medica plc

Charlie Cunningham +44 (0) 20 7600 1658
FinnCap

Billy Clegg / Edward Westropp / Annie Evangeli + 44 (0)20 7831 3113
Financial Dynamics


                    This information is provided by RNS
          The company news service from the London Stock Exchange

END

Contact Information

  • For further information please contact:

    Gosse B. Bruinsma
    M.D. +31 (0) 629 046 397
    Executive Chairman
    Curidium Medica plc

    Rob Smith
    +44 (0) 20 7383 5345
    Finance Director
    Curidium Medica plc

    Charlie Cunningham
    +44 (0) 20 7600 1658
    FinnCap

    Billy Clegg / Edward Westropp / Annie Evangeli
    + 44 (0)20 7831 3113
    Financial Dynamics